Aerovate Therapeutics (AVTE) Competitors $8.03 +0.13 (+1.65%) As of 08/26/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. IMNM, PHAR, QURE, AKBA, AVXL, SANA, ATAI, AVBP, OCS, and BGMShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Immunome (IMNM), Pharming Group (PHAR), uniQure (QURE), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Sana Biotechnology (SANA), atai Life Sciences (ATAI), ArriVent BioPharma (AVBP), Oculis (OCS), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Immunome Pharming Group uniQure Akebia Therapeutics Anavex Life Sciences Sana Biotechnology atai Life Sciences ArriVent BioPharma Oculis BGM Group Immunome (NASDAQ:IMNM) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is IMNM or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,687.08%. Immunome's return on equity of -76.10% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Immunome-1,687.08% -76.10% -65.14% Aerovate Therapeutics N/A -90.19%-77.47% Do insiders and institutionals have more ownership in IMNM or AVTE? 44.6% of Immunome shares are owned by institutional investors. 7.7% of Immunome shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, IMNM or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than Immunome. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M95.80-$292.96M-$3.08-3.23Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.72 Does the media prefer IMNM or AVTE? In the previous week, Immunome had 14 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 14 mentions for Immunome and 0 mentions for Aerovate Therapeutics. Immunome's average media sentiment score of 0.56 beat Aerovate Therapeutics' score of 0.00 indicating that Immunome is being referred to more favorably in the media. Company Overall Sentiment Immunome Positive Aerovate Therapeutics Neutral Do analysts prefer IMNM or AVTE? Immunome presently has a consensus price target of $22.50, indicating a potential upside of 126.13%. Given Immunome's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immunome is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, IMNM or AVTE? Immunome has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. SummaryImmunome beats Aerovate Therapeutics on 10 of the 15 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.75M$853.28M$5.74B$9.78BDividend YieldN/A4.84%4.40%4.04%P/E Ratio-2.691.1630.8326.39Price / SalesN/A138.93382.9086.63Price / CashN/A19.5637.7259.11Price / Book2.036.7710.106.62Net Income-$75.52M-$4.20M$3.26B$265.42M7 Day Performance9.10%11.77%3.90%3.58%1 Month Performance-3.02%3.47%3.73%0.46%1 Year Performance-87.80%15.88%37.68%19.41% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$8.03+1.6%N/A-88.4%$232.75MN/A-2.6920High Trading VolumeIMNMImmunome1.5638 of 5 stars$9.98-2.7%$23.14+131.9%-35.3%$868.49M$9.04M-3.2440Analyst ForecastPHARPharming Group2.3696 of 5 stars$12.01-3.1%$30.00+149.8%+73.8%$822.81M$297.20M-92.38280QUREuniQure2.3933 of 5 stars$14.88-5.0%$37.45+151.8%+158.0%$822.07M$14.34M-3.82500AKBAAkebia Therapeutics3.826 of 5 stars$3.05-2.1%$6.75+121.7%+99.4%$807.37M$203.73M-17.91430Analyst RevisionAVXLAnavex Life Sciences3.7442 of 5 stars$9.34-2.6%$44.00+370.9%+49.8%$797.87MN/A-16.3040News CoverageAnalyst ForecastSANASana Biotechnology3.0534 of 5 stars$3.34-1.7%$8.00+139.4%-44.9%$788.34MN/A-3.13380ATAIatai Life Sciences3.5724 of 5 stars$3.92-3.3%$11.25+187.4%+268.7%$784.33M$310K-5.6780AVBPArriVent BioPharma2.2976 of 5 stars$19.20-0.2%$39.14+103.9%-28.3%$778.74MN/A-4.7740Analyst UpgradeOCSOculis2.9738 of 5 stars$17.89-0.9%$35.33+97.5%+47.9%$778.46M$780K-6.752Positive NewsEarnings ReportAnalyst ForecastBGMBGM GroupN/A$8.00-1.8%N/A+38.5%$777.76M$25.10M0.00298Positive News Related Companies and Tools Related Companies Immunome Competitors Pharming Group Competitors uniQure Competitors Akebia Therapeutics Competitors Anavex Life Sciences Competitors Sana Biotechnology Competitors atai Life Sciences Competitors ArriVent BioPharma Competitors Oculis Competitors BGM Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access